Use of donor bone marrow mesenchymal stem cells for treatment of skin allograft rejection in a preclinical rat model

Archives of Dermatological Research

Volumn 300, Issue 3, 2008, Pages 115-124

  Sbano, Paolo ^a   Cuccia, Aldo ^a   Mazzanti, Benedetta ^b   Urbani, Serena ^b   Giusti, Betti ^c   Lapini, Ilaria ^c   Rossi, Luciana ^c   Abbate, Rosanna ^c   Marseglia, Giuseppina ^c   Nannetti, Genni ^c   Torricelli, Francesca ^c   Miracco, Clelia ^a   Bosi, Alberto ^b   Fimiani, Michele ^a   Saccardi, Riccardo ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

^c UNIVERSITY OF FLORENCE   (Italy)

Author keywords

CsA; Cytokine expression; Mesenchymal stem cells; Rat; Skin transplantation

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; SKIN ALLOGRAFT; SKIN BIOPSY; SKIN GRAFT REJECTION; SKIN TRANSPLANTATION; SPRAGUE DAWLEY RAT; THERAPY EFFECT; TREATMENT RESPONSE; WISTAR RAT;

ANIMALS; CYCLOSPORINE; CYTOKINES; GENE EXPRESSION; GRAFT ENHANCEMENT, IMMUNOLOGIC; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOSUPPRESSIVE AGENTS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SKIN TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 39949084861     PISSN: 03403696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00403-007-0827-9     Document Type: Article

References (40)

1. Aggarwal S, Pittenger MF (2005) Human mesenchymal stem cells modulate allogeneic immune cell response. Blood 105:1815-1822
2. Barber WH, Mankin JA, Laskow DA, Deierhoi MH, Julian BA, Curtis JJ, Diethelm AG (1991) Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation 1:70-75
3. Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R (2002) Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp Hematol 1:42-48
4. Chung NG, Jeong DC, Park SJ, Choi BO, Cho B, Kim HK, Chun CS, Won JH, Han CW (2004) Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int J Hematol 4:370-376
5. Demir Y, Ozmen S, Klimczak A, Mukherjee AL, Siemionow M (2004) Tolerance induction in composite facial allograft transplantation in the rat model. Plast Reconstr Surg 7:1790-1801
6. Dey B, Sykes M, Spitzer TR (1998) Outcomes of recipients of both bone marrow and solid organ transplants. A review. Medicine (Baltimore) 5:355-369
7. Djouad F, Plence P, Bony C, Tropel P, Apparailly F, Sany J, Noel D, Jorgensen C (2003) Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102:3837-3844
8. Djouad F, Fritz V, Apparailly F, Louis-Plence P, Bony C, Sany J, Jorgensen C, Noel D (2005) Reversal of the immunosuppressive properties of mesenchymal stem cells by tumor necrosis factor alpha in collagen-induced arthritis. Arthritis Rheum 5:1595-1603
9. Dobson KR, Reading L, Haberey M, Marine X, Scutt A (1999) Centrifugal isolation of bone marrow from bone: an improved method for the recovery and quantitation of bone marrow osteoprogenitor cells from rat tibiae and femurae. Calcif Tissue Int 5:411-413
10. Eliopoulos N, Stagg J, Lejeune L, Pommey S, Galipeau J (2005) Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice. Blood 13:4057-4065
11. Fehr T, Sykes M (2004) Tolerance induction in clinical transplantation. Transpl Immunol 2:117-130
12. Friedenstein AJ (1976) Precursor cells of mechanocytes. Int Rev Cytol 47:327-359
13. Gaciong Z, Koziak K, Religa P, Lisiecka A, Morzycka-Michalik M, Rell K, Kozlowska-Boszko B, Lao M (1995) Increased expression of growth factors during chronic rejection of human kidney allograft. Transplant Proc 27:928-929
14. Grinnemo KH, Mansson A, Dellgren G, Klingberg D, Wardell E, Drvota V, Tammik C, Holgersson J, Ringden, Sylven C, Le Blanc K (2004) Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J Thorac Cardiovasc Surg 5:1293-1300
15. Heslan JM, Renaudin K, Thebault P, Josien R, Cuturi MC, Chiffoleau E (2006) New evidence for a role of allograft accommodation in long-term tolerance. Transplantation 82:1185-1193
16. Inoue S, Popp FC, Koehl GE, Piso P, Schlitt HJ, Geisser EK, Dahlke MH (2006) Immunomodulatory effects of mesenchymal stem cells in a rat organ transplant model. Translantation 81:1589-1595
17. Khanna AK, Cairns VR, Becker CG, Hosenpud JD (1998) TGF-beta: a link between immunosuppression, nephrotoxicity, and CsA. Transplant Proc 4:944-945
18. Le Blanc K, Tammik L, Sundberg B, Haynesworth SE, Ringden O (2003) Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 1:11-20
19. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O (2004) Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 9419:1439-1441
20. Lim Yeon J, Jeun SS, Lee KJ, Oh JH, Kim SM, Park SI, Jeong CH, Kang SG (2006) Multiple stem cell traits of expanded rat bone marrow stromal cells. Exp Neurol 199:416-426
21. Liu Y, Song J, Liu W, Wan Y, Chen X, Hu C (2003) Growth and differentiation of rat bone marrow stromal cells: does 5-azacytidine trigger their cardiomyogenic differentiation? Cardiovasc Res 58:460-468
22. Maccario R, Moretta A, Cometa A, Montagna D, Comoli P, Locatelli F, Podesta M, Frassoni F (2005) Human mesenchymal stem cells and cyclosporin a exert a synergistic suppressive effect on in vitro activation of alloantigen-specific cytotoxic lymphocytes. Biol Blood Marrow Transplant 12:1031-1032
23. Mannon RB (2006) Therapeutic targets in the treatment of allograft fibrosis. Am J Transplant 6:867-875
24. Mathew JM, Garcia-Morales RO, Carreno M, Jin Y, Fuller L, Blomberg B, Cirocco R, Burke GW, Ciancio G, Ricordi C, Esquenazi V, Tzakis AG, Miller J (2003) Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol 3-4:307-321
25. Meisel R, Zibert A, Laryea M, Gobel U, Daubener W, Dilloo D (2004) Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 12:4619-4621
26. Monaco AP, Clark AW, Wood ML, Sahyoun AI, Codish SD, Brown RW (1976) Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery 4:384-392
27. Nauta AJ, Westerhuis G, Kruisselbrink AB, Lurvink EG, Willemze R, Fibbe WE (2006) Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a non-myeloablative setting. Blood 6:2114-2120
28. Petit F, Minns AB, Nazzal JA, Hettiaratchy SP, Lantieri LL, Randolph MA, Lee WP (2004) Prolongation of skin allograft survival after neonatal injection of donor bone marrow and epidermal cells. Plast Reconstr Surg 113:270-276
29. Pittenger MF, Mackay AM, Beck SC, Jaiswal RK, Douglas R, Mosca JD, Moorman MA, Simonetti DW, Craig S, Marshak DR (1999) Multilineage potential of adult human mesenchymal stem cells. Science 5411:143-147
30. Plain KM, Boyd R, Verma ND, Robinson CM, Tran GT, Hodgkinson SJ, Hall BM (2007) Transplant tolerance associated with a Th1 response and not broken by IL-4, IL-5, and TGF-beta blockade or Th1 cytokine administration. Transplantation 83:764-773
31. Rasmusson I, Ringden O, Sundberg B, Le Blanc K (2005) Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 1:33-41
32. Shapiro R, Starzl TE (1998) Bone marrow augmentation in renal transplant recipients. Transplant Proc 4:1371-1374
33. Sharma VK, Bologa RM, Xu GP, Li B, Mouradian J, Wang J, Serur D, Rao V, Suthanthiran M (1996) Intragraft TGF-beta 1 mRNA: a correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 49:1297-1303
34. Stagg J, Pommey S, Eliopoulos N, Galipeau J (2006) Interferon-gamma- stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell. Blood 6:2570-2577
35. Starzl TE, Demetris AJ, Trucco M, Murase N, Ricordi C, Ildstad S, Ramos H, Todo S, Tzakis A, Fung JJ (1993) Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology 6:1127-1152
36. Sudres M, Norol F, Trenado A, Gregoire S, Charlotte F, Levacher B, Lataillade JJ, Bourin P, Holy X, Vernant JP, Klatzmann D, Cohen JL (2006) Bone marrow mesenchymal stem cells suppress lymphocytes proliferation in vitro but fail to prevent graft-versus-host disease in mice. J Immunol 176:7761-7767
37. Taylor HR, Morris PJ (1970) Skin grafting in rats. Am J Med Technol 4:149-157
38. Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC (2003) Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 3:389-397
39. Wood ML, Gozzo JJ, Monaco AP (1972) Use of antilymphocyte serum and bone marrow for production of immunological tolerance and enhancement: review and recent experiments. Transplant Proc 4:523-529
40. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 5:1755-1761